Cost-Effectiveness Analysis of Qsymia for Weight Loss.

ABSTRACT:

Background

Phase 3 clinical trial results reveal that Qsymia is a clinically effective long-term treatment for obesity, but whether this treatment is cost-effective compared to a diet and lifestyle intervention has yet to be explored.

Objective

To quantify the incremental cost-effectiveness of Qsymia (phentermine and topiramate extended-release) for health-related quality of life improvements.

Study design and methods

Estimates are based on cost and quality of life outcomes from a 56-week, multicenter, placebo-controlled, phase 3 clinical trial undertaken in 93 health centers in the US. Participants were overweight and obese adults (aged 18-70 years) with a body-mass index of 27-45 kg/m(2) and two or more comorbidities (hypertension, dyslipidemia, diabetes or pre-diab

SUBMITTER: Finkelstein EA 

PROVIDER: S-EPMC4486409 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature